Ocular Therapeutix Stock Today
| OCUL Stock | USD 8.52 0.26 2.96% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Ocular Therapeutix is selling for 8.52 as of the 22nd of November 2024. This is a 2.96 percent decrease since the beginning of the trading day. The stock's lowest day price was 8.21. Ocular Therapeutix has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Ocular Therapeutix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of July 2014 | Category Healthcare | Classification Health Care |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. Ocular Therapeutix, Inc. The company has 157.22 M outstanding shares of which 12.67 M shares are now shorted by private and institutional investors with about 9.68 trading days to cover. More on Ocular Therapeutix
Moving against Ocular Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ocular Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Antony Mattessich | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsOcular Therapeutix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ocular Therapeutix's financial leverage. It provides some insight into what part of Ocular Therapeutix's total assets is financed by creditors.
| |||||
Ocular Therapeutix (OCUL) is traded on NASDAQ Exchange in USA. It is located in 15 Crosby Drive, Bedford, MA, United States, 01730 and employs 267 people. Ocular Therapeutix is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.34 B. Ocular Therapeutix conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 157.22 M outstanding shares of which 12.67 M shares are now shorted by private and institutional investors with about 9.68 trading days to cover.
Ocular Therapeutix currently holds about 134.54 M in cash with (70.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.75.
Check Ocular Therapeutix Probability Of Bankruptcy
Ownership AllocationOcular Therapeutix owns a total of 157.22 Million outstanding shares. The majority of Ocular Therapeutix outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Ocular Therapeutix to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Ocular Therapeutix. Please pay attention to any change in the institutional holdings of Ocular Therapeutix as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ocular Ownership Details
Ocular Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 3.7 M | |
| Geode Capital Management, Llc | 2024-06-30 | 3.5 M | |
| Perceptive Advisors Llc | 2024-09-30 | 3.3 M | |
| Assenagon Asset Management Sa | 2024-09-30 | 2.8 M | |
| Point72 Asset Management, L.p. | 2024-06-30 | 2.7 M | |
| Deltec Asset Management Llc | 2024-09-30 | 2.6 M | |
| Octagon Capital Advisors Lp | 2024-06-30 | 2.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.3 M | |
| Braidwell Lp | 2024-09-30 | 2.2 M | |
| Summer Road Llc | 2024-06-30 | 14.9 M | |
| Vr Adviser, Llc | 2024-06-30 | 12.8 M |
Ocular Therapeutix Historical Income Statement
Ocular Stock Against Markets
Ocular Therapeutix Corporate Management
| William Slattery | Vice Relations | Profile | |
| Todd Anderman | Chief Secretary | Profile | |
| William II | Vice Marketing | Profile | |
| Peter MD | Chief Officer | Profile | |
| Donald Notman | Chief Officer | Profile | |
| Philip Esq | General Counsel | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.